Company

Emergent BioSolutions

Emergent BioSolutions has 32 drugs tracked on RxWires: 5 post-market, 6 in Phase 3, 1 in Phase 2/3, 8 in Phase 2, 1 in Phase 1/2, 11 in Phase 1.

Pipeline

Drug	Phase	Indication
Vaccination with ACAM2000	Post-Market	Smallpox Vaccine Adverse Reaction
AVA	Post-Market	Infections, Bacterial
Blood sample collection	Post-Market	Botulism
Sample Collection	Post-Market	Infections, Bacterial
VAXCHORA (Cholera Vaccine, Live, Oral)	Post-Market	Cholera (Disorder)
AV7909	Phase 3	Anthrax
raxibacumab	Phase 3	Healthy
CHIKV VLP/adjuvant	Phase 3	Chikungunya Virus
BioThrax	Phase 3	Anthrax
PXVX0200	Phase 3	Cholera
ACAM2000	Phase 3	Smallpox Vaccine Adverse Reaction
HuMax-CD4	Phase 2/3	T Cell Lymphoma
ACAM2000 Smallpox Vaccine	Phase 2	Smallpox
PXVX0200 10E8	Phase 2	Cholera
Vaccinia virus: ACAM2000 smallpox vaccine	Phase 2	Smallpox
FLU-IGIV	Phase 2	Influenza A H3N2
Dose of 5.0 x 10^9 CFU (Cohort 1)	Phase 2	Typhoid
Chikungunya	Phase 2	Chikungunya
CHOP + CD4	Phase 2	T-cell Lymphoma
Ciprofloxacin 500Mg Tablet	Phase 2	Anthrax
AIGIV 3.5 mg/kg	Phase 1/2	Anthrax
16 mg naloxone AP003	Phase 1	Opioid Overdose
Stabilized Isoamyl Nitrite (SIAN)	Phase 1	Cyanide Poisoning
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)	Phase 1	Healthy
Ad4-mgag	Phase 1	Healthy Volunteer
COVID-HIGIV	Phase 1	COVID-19
COVID-HIG	Phase 1	SARS-CoV-2 Infection
Brincidofovir	Phase 1	Smallpox
UV-4B 3 mg	Phase 1	Viral Infection
AVP-21D9	Phase 1	Anthrax
AERAS-402	Phase 1	Tuberculosis
Ad4-H5-Vtn	Phase 1	Bird Flu

Follow Emergent BioSolutions on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.